Browsing Tag
Drug discovery
43 posts
The new engine of drug discovery? Inside Thermo Fisher Scientific’s cryo-EM hub in the Bay Area
Thermo Fisher Scientific opens a cryo-EM drug discovery center in South San Francisco to accelerate structural biology research. Discover why this matters for pharma.
Syntheia signs LOI to acquire SATCO, targeting lab data integration in pharma R&D workflows
Syntheia signs LOI to acquire SATCO and expand its pharma R&D data stack. Explore how this deal could reshape structured content workflows for life sciences.
How NVIDIA is embedding BioNeMo into life sciences R&D as AI-driven drug discovery scales commercially
Find out how NVIDIA is embedding BioNeMo into life sciences R&D as AI-driven drug discovery scales commercially across enterprise research pipelines.
Can Genesis Molecular AI leap ahead in biotech with Meta’s Llama leader now onboard?
Genesis Molecular AI hires Meta's Llama leader Sergey Edunov to lead foundation models. Discover how this move strengthens its AI drug discovery platform.
N2OFF enters cancer-drug discovery market through MitoCareX merger
Find out how N2OFF’s merger with MitoCareX is reshaping its business and targeting pancreatic & lung cancers!
Shuttle to enter $3.24bn AI pharmaceutical market via acquisition of Molecule.ai
Find out how Shuttle Pharmaceuticals’ $10 million acquisition of Molecule.ai could reshape its R&D strategy and redefine the $3.24 billion AI pharma landscape.
Absci goes full throttle on AI drug design with Oracle and AMD in its corner
Absci taps Oracle Cloud and AMD’s Instinct GPUs to fast-track AI-powered drug discovery and antibody design. Find out what this means for biotech’s future.
Can Norma’s NVIDIA-backed quantum AI breakthrough finally scale drug development?
Find out how Norma’s quantum AI achieved 73× faster drug discovery on NVIDIA CUDA-Q, and what it means for biotech, finance, and defense.
Recursion Pharmaceuticals (NASDAQ: RXRX) stock rises after 20% workforce cut and pipeline reset
Recursion Pharmaceuticals (NASDAQ: RXRX) cuts 20% of workforce to extend runway and narrow pipeline focus—read what this means for its AI drug discovery strategy.
Atai Life Sciences acquires exclusive rights to Psilera’s DMT patent portfolio
Atai Life Sciences has taken a strategic step in expanding its position in psychedelic medicine by securing exclusive…